miR-34a expression in the serum of relapsing and remitting multiple sclerosis
Author(s): DAI Hui-yu
Pages: 478-480,484
Year: 2017 Issue: 5
Journal: Clinical Journal of Medical Officer
Keyword: Multiple sclerosis; Serum biomarker; Acute relapsing period; Remission;
Abstract: Objective To detect the expression of miR-34a in relapsing-remitting multiple sclerosis(RRMS)of peripheral blood serum in acute relapse phase and remission stage,investigate the possibility of it as a new serum markers and the relationship between the serum and active disease.Methods A retrospective study was performed on RRMS patients who were admitted from January 2014 to December 2015.The 20 RRMS patients in the acute and remit phase were divided into the observation group,patients were in acute and remit phase without any treatment;all the patients were followed up and were not treated with medication(immunoregulatory medication)during the period of relief.At the same time,another 20 healthy volunteers whose age and gender were matched with the ones in the observation group were selected in the healthy group.The total RNA from the cell-free serum samples were extracted,using RT-Qpcr assay to test the expression of miR-34a according to the results of preliminary experiments in order to screen differentially expressed microRNAs as potential serum biomarkers for multiple sclerosis(MS)in the acute relapse group and the healthy group.Results Acute phase MS group showed an down-regulation of miR-34a,with an average fold change of 1.91(P<0.05);there was no statistically significant difference of miR-34a between observation group in relapsing period and healthy group(P>0.05).Conclusion miR-34a is down-regulated in the serum of acute phase MS patients,it may serve as a potential serum biomarker for multiple sclerosis.
Pages: 478-480,484
Year: 2017 Issue: 5
Journal: Clinical Journal of Medical Officer
Keyword: Multiple sclerosis; Serum biomarker; Acute relapsing period; Remission;
Abstract: Objective To detect the expression of miR-34a in relapsing-remitting multiple sclerosis(RRMS)of peripheral blood serum in acute relapse phase and remission stage,investigate the possibility of it as a new serum markers and the relationship between the serum and active disease.Methods A retrospective study was performed on RRMS patients who were admitted from January 2014 to December 2015.The 20 RRMS patients in the acute and remit phase were divided into the observation group,patients were in acute and remit phase without any treatment;all the patients were followed up and were not treated with medication(immunoregulatory medication)during the period of relief.At the same time,another 20 healthy volunteers whose age and gender were matched with the ones in the observation group were selected in the healthy group.The total RNA from the cell-free serum samples were extracted,using RT-Qpcr assay to test the expression of miR-34a according to the results of preliminary experiments in order to screen differentially expressed microRNAs as potential serum biomarkers for multiple sclerosis(MS)in the acute relapse group and the healthy group.Results Acute phase MS group showed an down-regulation of miR-34a,with an average fold change of 1.91(P<0.05);there was no statistically significant difference of miR-34a between observation group in relapsing period and healthy group(P>0.05).Conclusion miR-34a is down-regulated in the serum of acute phase MS patients,it may serve as a potential serum biomarker for multiple sclerosis.
Related Articles